Encouraging sign for OSE on Phase III immuno-oncology trial

25 January 2017

Shares in OSE Immunotherapeutics (OSE: PA) are up around 4% following the news that an independent body charged with monitoring the company’s trial data has recommended continuation of the company’s Phase III study into its immuno-oncology drug Tedopi.

The body of independent experts was set up by the French company to assess the progress, safety data and critical efficacy endpoints of the clinical trial. The recommendation to continue was unanimous, and no modifications were requested.

The study is designed to evaluate the benefits of Tedopi compared to current standard chemotherapies in certain patients with non-small-cell lung carcinoma. Tedopi is a patented combination of 10 epitopes, selected and optimized from five tumor associated antigens.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK